In this issue:
- Continued efficacy of ibrutinib in older adults with CLL
- 3 years of axicabtagene ciloleucel for relapsed/ refractory non-Hodgkin lymphoma
- Early CR as marker for extranodal marginal zone lymphoma systemic therapy
- Long-term results of dasatinib-blinatumomab protocol for Ph+ ALL
- 6-year follow-up and subgroup analyses of venetoclax for del(17p) CLL
- Daratumumab-based quadruplets for newly diagnosed high-risk MM
- Outcomes for MM refractory to standard- vs. low-dose lenalidomide
- T-cell redirecting therapies in triple-class refractory MM
- Postinduction MRD identifies allogeneic SCT in first CR benefit in NPM1 AML
- Alternative donor SCT for severe aplastic anaemia
Please login below to download this issue (PDF)